FDA Drug Safety Process Subject To IoM Review Under Agency Initiative
This article was originally published in The Tan Sheet
Executive Summary
FDA will sponsor an Institute of Medicine study of the agency's drug safety process as part of a broad initiative to strengthen the pre- and post-market evaluation of drugs